S&P TSX Capped Composite...

US Dollar vs CAD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

NRIX Nurix Therapeutics Inc

18.24

-1.27 (-6.51%)

Jan 10 2025 - Closed

Delayed by 15 minutes

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Nurix Therapeutics (NASDAQ:NRIX)
Historical Stock Chart
From Dec 2024 to Jan 2025

Click Here for more Nurix Therapeutics Charts.

Nurix Therapeutics (NASDAQ:NRIX)
Historical Stock Chart
From Jan 2024 to Jan 2025

Click Here for more Nurix Therapeutics Charts.

Nurix Therapeutics Inc News

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Friday 10 January 2025 (6 hours ago) • Edgar (US Regulatory)

Nurix Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Monday 6 January 2025 (5 days ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 2 January 2025 (1 week ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Thursday 2 January 2025 (1 week ago) • Edgar (US Regulatory)

Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom’s Macroglobulinemia
Thursday 19 December 2024 (3 weeks ago) • GlobeNewswire Inc.

Form 8-K - Current report
Tuesday 10 December 2024 (1 month ago) • Edgar (US Regulatory)

Nurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual Meeting
Monday 9 December 2024 (1 month ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Monday 2 December 2024 (1 month ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Monday 2 December 2024 (1 month ago) • Edgar (US Regulatory)

Nurix Therapeutics Announces Webcast To Review New Data from Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented at the 66th American Society of Hematology (ASH) Annual Meeting
Monday 2 December 2024 (1 month ago) • GlobeNewswire Inc.

Nurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
Monday 25 November 2024 (2 months ago) • GlobeNewswire Inc.

Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia
Wednesday 20 November 2024 (2 months ago) • GlobeNewswire Inc.

More Nurix Therapeutics Inc News Articles

Bassari Resources

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions